NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE
Post# of 341
(Total Views: 194)
Posted On: 10/11/2021 2:59:13 PM
NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Poised Amid New Research Surrounding Psilocybin
Cybin (NEO: CYBN) (NYSE American: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, is likely to benefit from new research touting psilocybin mental health treatments. According to recent news from a group of Yale researchers, psilocybin has been found to counteract symptoms of depression (https://nnw.fm/YBH97). “Yale researchers found that a single dose of the naturally occurring psychedelic compound psilocybin can cause structural changes in the brain that counteract symptoms of depression,” reads a recent article quoting a Yale Daily News publication titled “Yale Researchers Discover Healing Effects of Psychedelic Drug.” In the piece published in the Neuron journal, researchers at the Yale School of Medicine “presented evidence that administering this drug to mice resulted in an approximately 10% increase in neuron size and density in the frontal cortex of the brain. Led by postdoctoral associate Lingxiao Shao and associate professor of psychiatry and neuroscience Alex Kwan, the team found that this ‘structural remodeling’ occurred within 24 hours of the drug administration and persisted for one month, indicating that psilocybin made long-lasting changes in the brain.” Studies such as this serve to validate and strengthen the work done by Cybin, which is on a mission to revolutionize mental health care.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Cybin (NEO: CYBN) (NYSE American: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, is likely to benefit from new research touting psilocybin mental health treatments. According to recent news from a group of Yale researchers, psilocybin has been found to counteract symptoms of depression (https://nnw.fm/YBH97). “Yale researchers found that a single dose of the naturally occurring psychedelic compound psilocybin can cause structural changes in the brain that counteract symptoms of depression,” reads a recent article quoting a Yale Daily News publication titled “Yale Researchers Discover Healing Effects of Psychedelic Drug.” In the piece published in the Neuron journal, researchers at the Yale School of Medicine “presented evidence that administering this drug to mice resulted in an approximately 10% increase in neuron size and density in the frontal cortex of the brain. Led by postdoctoral associate Lingxiao Shao and associate professor of psychiatry and neuroscience Alex Kwan, the team found that this ‘structural remodeling’ occurred within 24 hours of the drug administration and persisted for one month, indicating that psilocybin made long-lasting changes in the brain.” Studies such as this serve to validate and strengthen the work done by Cybin, which is on a mission to revolutionize mental health care.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Cybin Inc (CYBN) Stock Research Links
Scroll down for more posts ▼